• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Andy Bolan

2018-11-05News

What is your current role in EPAD?

I am a brand-new member of the EPAD work package six. Having joined the Alzheimer’s team at Biogen in May 2018, the EPAD work was highlighted as a key coalition to join and support from a communications and advocacy perspective. I bring to the team over six years of experience in working with the pharmaceutical industry across a wide range of corporate affairs competencies, including: patient advocacy, government affairs, communications (internal and external) and stakeholder relations. I hope to support the work package with the next stages of the project including the run up to month 60.  

What did you do prior to joining EPAD?

I am a patient advocacy and corporate affairs professional by trade with over six years’ experience of working in the life sciences sector. Before joining Biogen and the EPAD work package six, I have worked in a range of national, regional and global pharmaceutical roles striving to bring the patient voice closer to company corporate policy. Currently based in Amsterdam with Biogen, I moved to the Netherlands for a Global Patient Advocacy role with Teva Pharmaceuticals, and before that I held a variety of Corporate Affairs roles in Westminster with the Association of the British Pharmaceutical Industry.

Working in the pharmaceutical and life sciences sector has given me an understanding of the industries issues and their contribution to research, health, wellbeing and economic success. It is fundamental for companies and research organizations to have a clear patient advocacy and communications strategy to engage and educate governments, policy makers and the general public. 

Tell us a bit about the institution/company/organization you work for.

I am the Senior Manager, EU Patient Advocacy, Alzheimer’s Disease at Biogen. Biogen was founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

Biogen currently works across a wide range of neurological conditions including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS), as well as less common diseases such as Spinal Muscular Atrophy (SMA) and Progressive Supranuclear Palsy (PSP).

Biogen has a collaborative approach to our research, engaging with physicians and scientific leaders around the world with the aim to further medical research, alongside working with advocacy and patient organizations as they serve the communities they represent. It was this strong scientific approach to tackling diseases that really drew me to work for Biogen.

What are your expectations from the EPAD project?

EPAD really embodies the future of research in healthcare. The initiative really is a unique European project aimed at tackling some of the challenges in Alzheimer’s Disease research. My expectations center on the need for Work Package six to communicate the weight of information EPAD is creating. As the largest ever public-private partnership in Alzheimer’s disease research, work package six has a huge role in communicating the combined knowledge and expertise of 38 organisations across multiple sectors. Alongside championing the research milestones and new research advances.

 

 

 

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
EPAD v1500 dataset
New webpage dedicated to EPAD data and samples on the EPAD website
2020-11-18
ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
2020-11-17
New paper investigating the prediction of Alzheimer’s disease biomarker status
2020-11-12
The Alzheimer’s Disease Data Initiative supports EPAD
2020-11-06
Latest News
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
  • ALZFORUM
    Alzforum conference blog mentions EPAD
    2020-11-30
  • EPAD v1500 dataset
    New webpage dedicated to EPAD data and samples on the EPAD website
    2020-11-18
  • ADDI launches new Workbench to foster greater global research innovation and accelerate breakthroughs in Alzheimer’s disease and related dementias
    2020-11-17
  • New paper investigating the prediction of Alzheimer’s disease biomarker status
    2020-11-12
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

We would like to thank all our followers! A massive thanks also goes to our research participants & members for all their support! Looking back on the years of the @IMI_EPAD project, here's key pictures took at major events. Have a safe & Happy New Year! youtu.be/FeYsOBOhCeo

reply retweet favorite
8:55 am · 2021-01-18
Twitter
EPAD
EPAD
@IMI_EPAD

The videos from #30AEC are online! Check out the @IMI_EPAD presentations on #data sharing by @rodrigobarnes (@aridhia) & Colin Veal (@uniofleicester). Thanks @IMI2_NEURONET and @AlzheimerEurope for giving us the opportunity to present our work. imi-neuronet.org/2020-virtual… twitter.com/IMI2_NEURONET/…

reply retweet favorite
8:43 am · 2021-01-15
Twitter
EPAD
EPAD
@IMI_EPAD

Authors investigated #data from nine studies, including @IMI_EPAD, comprising a total of 60,004 assessed participants. If you want to explore the #Alzheimer's disease data landscape, visit adata.scai.fraunhofer.de @BirkenbihlC @ApitiusHofmann @ddomingof @Simon_Lovestone @TVB_cloud

reply retweet favorite
7:56 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

Numerous studies have collected #Alzheimer's disease cohort #data sets. @BirkenbihlC and colleagues have evaluated the Alzheimer's disease data landscape from a patient‐level data‐centric perspective. @IMI_EPAD @IMI_EMIF @NACCALZ alz-journals.onlinelibrary.wi…

reply retweet favorite
7:48 am · 2021-01-11
Twitter
EPAD
EPAD
@IMI_EPAD

The final @IMI_EPAD dataset is now available to the entire research community | News | @CORDIS_EU | European Commission europa.eu/!dj89jY

reply retweet favorite
12:55 pm · 2021-01-08
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.